INTRODUCTION
============

Upper tract urothelial carcinoma (UTUC) is a rare disease that accounts for approximately 5% of all urothelial malignancies, and radical nephroureterectomy with bladder cuff excision (RNU) is the standard treatment of UTUC[@B1]. The pathological features and clinical behavior of UTUC are very similar to those of bladder urothelial carcinoma, thus urologists consider them to be nearly the same disease. Tumor stage, nuclear grade, lymphovascular invasion, and node metastasis are valuable prognostic factors of UTUC. On the other hand, there are some controversies regarding the prognostic value of tumor location, tumor size, and adjuvant chemotherapy[@B2]-[@B9]. Studies have demonstrated the value of neoadjuvant chemotherapy for locally advanced bladder carcinoma[@B10]-[@B12], and some series have reported a survival benefit of chemotherapy in metastatic UTUC[@B13]. Locally advanced non-metastatic UTUC is associated with poor survival, and there is no standardized therapy conferring a survival benefit after RNU. The only prospective randomized clinical trial - the POUT (peri-operative chemotherapy versus surveillance in upper tract urothelial cancer) trial just started in April 2012 in United Kingdom[@B14]. Some urologists administer adjuvant chemotherapy after RNU although there is a lack of data supporting its efficacy of in UTUC. Therefore, we assessed the significance of adjuvant chemotherapy in UTUC after RNU focusing on survival.

MATERIAL AND METHODS
====================

The study flow chart is described in Fig. [1](#F1){ref-type="fig"}. After obtaining institutional review board approval, we retrospectively reviewed the medical records of 145 patients diagnosed with UTUC between January 2000 and January 2013. Among them, a total of 65 patients had non-metastatic, locally advanced upper tract urothelial cell carcinoma (pT3 or pT4 or pT1-2N1-3) after undergoing RNU. We performed radical nephroureterectomy with bladder cuff resection by laparoscopic and open approach. Hilar lymph node was routinely removed in all our procedures. In cases of presence of hyperplastic lymph nodes, beside the great vessel or hilum we tried to resect grossly visible or palpable lymph node as meticulously as possible. After discharge, patients re-visited out-patient clinic, then we explained the potential benefit (survival gain) and disadvantage of adjuvant chemotherapy (uncertainty of survival benefit, chemo-toxicities, medical co-morbidity, financial problem) to these patients. After gathering chemotherapy candidates, we checked creatinine clearance of these patients between 2 and 4 weeks after operation for making optimal dose of cisplatin. The first cycle of chemotherapy was performed within 4 weeks. A total of 36 patients received at least three cycles of adjuvant gemcitabine plus cisplatin chemotherapy while remaining 29 patients did not go through chemotherapy due to uncertainty of chemo-toxicities (13 patients), survival benefit (7 patients), medical co-morbidities (5 patients) and financial issues (4 patients). The chemotherapy patients were administered 1000 mg/m^2^ gemcitabine on day 1, 8, and 15 and 70 mg/m^2^ cisplatin on day 2 for the GC regimen. The dose of cisplatin was reduced from 50 to 70% of normal dose when estimated glomerular filtration rate was under 70ml/minutes. After RNU or adjuvant chemotherapy, the patients received follow-up of routine hematology and biochemistry, cystoscopy, urinary cytology, simple chest x-ray every three months for the first two years, every six months in the next two years, and annually thereafter. Abdominopelvic CT scan was performed every six months in the first two years then annually afterward. We retrospectively reviewed medical records for clinical data and radiologic findings. Pathologic stage and nuclear grade were analyzed according to the AJCC (American Joint Committee on Cancer) and 1998 WHO/International Society of Urologic Pathology consensus classification[@B15].

The characteristics of the chemotherapy group and non-chemotherapy group were analyzed using Fisher\'s exact test. Bladder recurrence free survival and cancer-specific survival were assessed using the Kaplan-Meier method and compared between the two groups using the log-rank test. The prognostic significance of clinical variables was evaluated by the Cox proportional hazards model, and a p-value \< 0.05 was considered statistically significant for all analyses.

RESULTS
=======

Patient characteristics
-----------------------

The mean age of the 65 patients was 60.4 (range, 37-87) years and the median follow-up period was 34 (range, 12-114) months. Perioperative clinical data were not statistically different between the two groups, except bladder recurrence. Detailed characteristics of each patient group are summarized in Table [1](#T1){ref-type="table"}.

Recurrence and survival
-----------------------

During follow-up period, 14 patients (21.5%) experienced distant metastasis, 8 (8/36, 22.2%) of whom underwent adjuvant chemotherapy while the remaining 6 (6/29, 20.7%) patients did not. Bladder recurrence was noted in 17 patients (26.2%) at a median of 8 months (range, 3-30), 5 (5/36, 13.9%) in the adjuvant chemotherapy group and 12 (12/29, 41.4%) in the group that did not receive chemotherapy. On multivariate cox proportional hazard model analysis, bladder recurrence was significantly higher in patients who did not undergo adjuvant chemotherapy (p=0.001, HR=14.862), and cancer-specific survival was significantly associated with lymph node involvement (p\<0.001, HR=42.78). Cancer-specific survival was not associated with adjuvant chemotherapy (Tables [2](#T2){ref-type="table"}). In Kaplan-Meier analysis, the bladder recurrence free survival was significantly higher in adjuvant chemotherapy group than non-chemotherapy group (log-rank test, p=0.026). However, there was no significant difference in the cancer-specific survival (log-rank test, p=0.47) (Figure [2](#F2){ref-type="fig"}).

DISCUSSION
==========

Advanced UTUC is difficult to treat because of the poor survival rate and high rate of recurrence. The five-year survival rate of low stage (pT1) UTUC is known to be greater than 90%. However, pT3 stage UTUC has a poor five-year survival rate of approximately 50%, and this rate decreases to 5% in pT4 stage disease[@B2]. This discrepancy in survival rate between low and high stage UTUC have led urologic oncologist to recommend further treatment.

The survival benefit of neoadjuvant chemotherapy before radical cystectomy in patients with invasive bladder carcinoma has been demonstrated[@B10]-[@B12]; however, the efficacy of adjuvant chemotherapy after radical cystectomy remains controversial[@B9]. As is the case for bladder carcinoma, there are limited data on the efficacy of adjuvant chemotherapy for UTUC. Until the results of POUT trials or other randomized prospective clinical trials are to be revealed, some will give adjuvant chemotherapy without any reliable data while others will not due to an uncertainty of benefit[@B14]. Further complicating the issue, uro-oncologists may hesitate to administer chemotherapeutic agents after RNU based on concern over nephrotoxicity to the solitary kidney.

Kwak et al. suggested that adjuvant chemotherapy for high-risk UTUC (including stage pT2) can provide a therapeutic benefit[@B16]; however, Lee et al. reported that there was no significant difference in cancer-specific survival or recurrence-free survival between an adjuvant chemotherapy group and non-chemotherapy group[@B17]. According to the largest study to date conducted by Hellenthal, adjuvant chemotherapy has no survival benefit for high-risk UTUC[@B18]. In our study, 19 patients died during the follow-up period due to disease progression; however, there was no significant difference in survival between the adjuvant chemotherapy and non-chemotherapy groups. Hisataki et al. reported that most instances of recurrence developed within two years after RNU, and the majority of bladder recurrence cases (19 of 22 bladder recurrent patients) in UTUC were non-muscle invasive bladder cancers[@B19]. Our study showed similar results. A total of 17 patients experienced bladder recurrence at a median of 8 months. However, all bladder recurrences were non-muscle invasive bladder cancers and could be treated by transurethral resection with intravesical BCG or mitomycin C instillation.

Cho et al. reported that baseline creatinine clearance decreased below 60 ml/min in 83.3% of patients after nephroureterectomy. However, the majority of patients with a solitary kidney underwent cisplatin-based chemotherapy without serious adverse events[@B20]. We also believe that nephrotoxicity to the single renal unit is not a major concern in adjuvant chemotherapy. In our analysis, known prognostic factors such as lymphovascular invasion, tumor location (ureter or renal pelvis), and nuclear grade were not significantly associated with survival. These results may be due to the fact that we included only patient with stage pT3 or pT4 disease. If we had included cases of pT1 or pT2 disease, these prognostic factors may have been significant. Some investigators reported that tumor location is an independent risk factor for bladder recurrence[@B21],[@B22]. On the other hand, others suggested that multifocality and concomitant CIS are the significant risk factors[@B23]. In our study, these known risk factors for bladder recurrence were not significant; adjuvant chemotherapy was the only significant factor for bladder recurrence. The studies mentioned above included all stages of UTUC, and the fact that we included only cases with high stage disease is likely the reason underlying the lack of statistical significance observed between commonly accepted prognostic factors and recurrence or survival. Soga et al. reported that adjuvant M-VAC chemotherapy reduced bladder recurrence in stage pT2 or higher UPTC[@B24]. That study was performed over 20 years; patients received adjuvant chemotherapy during the first 10 years of the study period while they did not during the latter 10 years. The fact that the chemotherapy and non-chemotherapy groups were not enrolled during the same period indicates the potential for selection bias.

According to our study, cisplatin-based adjuvant chemotherapy for UTUC has no influence on cancer-specific survival. However, adjuvant chemotherapy can reduce bladder recurrence, thereby preventing transurethral resection of recurrent bladder tumors and intravesical therapy. Nevertheless, bladder recurrence was not associated with cancer-specific survival because these patients were cured with transurethral resection of the recurrent bladder tumor with or without intravesical therapy. If patients with advanced UTUC do not receive adjuvant chemotherapy, there is a higher possibility of bladder recurrence. However, adjuvant chemotherapy and bladder recurrence did not have a significant effect on cancer-specific survival in this study. Uro-oncologists should consider the toxicities of chemotherapy and patient compliance and financial status when determining whether chemotherapy is appropriate.

CONCLUSION
==========

Due to similarities with the pathological features of bladder carcinoma, adjuvant chemotherapy for locally advanced UTUC is often suggested. However, our findings suggest that adjuvant chemotherapy for locally advanced UTUC can prevent bladder recurrence but has a minimal effect on cancer-specific survival. Prospective randomized clinical trials are necessary to verify the effect of adjuvant chemotherapy on locally advanced UTUC.

![Study flow diagram.](jcav04p0686g001){#F1}

![**Kaplan-Meier analyses of bladder recurrence free survival and cancer-specific survival.** In Kaplan-Meier analysis, bladder recurrence free survival was significantly higher in adjuvant chemotherapy group than non-chemotherapy group (A; log-rank test, p=0.026). However, there was no significant difference in the cancer-specific survival (B; log-rank test, p=0.47).](jcav04p0686g002){#F2}

###### 

The patients\' characteristics.

                                            Chemotherapy (n=36)   No chemotherapy (n=29)   Total (n=65)   p-value
  ----------------------------------------- --------------------- ------------------------ -------------- ---------
  **Age (year)**                                                                                          0.273
  \< 60                                     22                    12                       34             
  ≥ 60                                      14                    17                       31             
  **Gender**                                                                                              0.820
  male                                      19                    21                       40             
  female                                    17                    8                        25             
  **Tumor location**                                                                                      0.914
  renal pelvis                              26                    20                       46             
  ureter                                    10                    9                        19             
  **Pathological tumor stage**                                                                            0.125
  pT1-2N1-3                                 2                     0                        2              
  pT3N0-3                                   30                    27                       57             
  pT4N0-3                                   4                     2                        6              
  **Nuclear grade (WHO)**                                                                                 0.388
  grade 1/2                                 4                     6                        10             
  grade 3                                   32                    23                       55             
  **Lymphovascular invasion**                                                                             0.266
  (-)                                       22                    16                       38             
  (+)                                       24                    13                       27             
  **Lymph node**                                                                                          0.458
  (-)                                       28                    26                       54             
  (+)                                       8                     3                        11             
  **Urine cytology**                                                                                      0.553
  (-)                                       16                    12                       28             
  (+)                                       20                    17                       37             
  **Bladder recurrence**                                                                                  0.001
  (-)                                       31                    17                       48             
  (+)                                       5                     12                       17             
  **Distant metastasis during follow-up**                                                                 0.590
  (-)                                       28                    23                       51             
  (+)                                       8                     6                        14             

###### 

Multivariate analysis for predicting bladder recurrence and cancer-specific free survival.

                   Bladder recurrence   Cancer-specific free survival                                
  ---------------- -------------------- ------------------------------- ------- ------- ------------ -------
  Age              1.22                 0.39-3.72                       0.631   1.50    0.75-3.53    0.221
  Gender           0.23                 0.03-1.84                       0.149   0.57    0.21-1.64    0.171
  Tumor location   0.78                 0.32-2.85                       0.482   1.62    0.54-6.21    0.438
  Nuclear grade    1.84                 0.46-7.35                       0.359   3.85    0.70-18.3    0.094
  LNI              1.23                 0.41-3.86                       0.761   42.78   8.7-210.36   0.000
  LVI              0.82                 0.16-6.10                       0.635   1.86    0.57-5.40    0.337
  Urine cytology   1.78                 0.43-7.26                       0.325   1.33    0.81-2.36    0.110
  ACT              14.862               3.20-68.99                      0.001   1.94    0.55-5.77    0.210

HR : hazard ratio, CI : confidence interval, LNI : lymph node involvement, LVI : lymphovascular invasion, ACT : adjuvant chemotherapy.
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